Details for New Drug Application (NDA): 020205
✉ Email this page to a colleague
NDA 020205 describes PSORCON, which is a drug marketed by Taro Pharms North and Pfizer and is included in three NDAs. Additional details are available on the PSORCON profile page.
The generic ingredient in PSORCON is diflorasone diacetate. There are three drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the diflorasone diacetate profile page.
The generic ingredient in PSORCON is diflorasone diacetate. There are three drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the diflorasone diacetate profile page.
Summary for 020205
| Tradename: | PSORCON |
| Applicant: | Taro Pharms North |
| Ingredient: | diflorasone diacetate |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | CREAM;TOPICAL | Strength | 0.05% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Nov 20, 1992 | TE: | RLD: | Yes | |||||
Complete Access Available with Subscription
